DE69431568T2 - Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen - Google Patents

Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen

Info

Publication number
DE69431568T2
DE69431568T2 DE69431568T DE69431568T DE69431568T2 DE 69431568 T2 DE69431568 T2 DE 69431568T2 DE 69431568 T DE69431568 T DE 69431568T DE 69431568 T DE69431568 T DE 69431568T DE 69431568 T2 DE69431568 T2 DE 69431568T2
Authority
DE
Germany
Prior art keywords
compounds
proliferation
migration
hydroxycarbazol
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69431568T
Other languages
English (en)
Other versions
DE69431568D1 (de
Inventor
Tian-Li Yue
H Ohlstein
Z Feuerstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Mannheim Pharmaceuticals Corp-Smithkline Beecham Corp No 1 Gaithersburg LP
Roche Diagnostics Corp
Original Assignee
Boehringer Mannheim Pharmaceuticals Corp-Smithkline Beecham Corp No 1 Gaithersburg LP
Boehringer Mannheim Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharmaceuticals Corp-Smithkline Beecham Corp No 1 Gaithersburg LP, Boehringer Mannheim Pharmaceuticals Corp filed Critical Boehringer Mannheim Pharmaceuticals Corp-Smithkline Beecham Corp No 1 Gaithersburg LP
Application granted granted Critical
Publication of DE69431568D1 publication Critical patent/DE69431568D1/de
Publication of DE69431568T2 publication Critical patent/DE69431568T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69431568T 1993-11-24 1994-11-22 Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen Expired - Fee Related DE69431568T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/157,588 US5393772A (en) 1993-11-24 1993-11-24 Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
PCT/US1994/013561 WO1995014384A1 (en) 1993-11-24 1994-11-22 Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds

Publications (2)

Publication Number Publication Date
DE69431568D1 DE69431568D1 (de) 2002-11-21
DE69431568T2 true DE69431568T2 (de) 2003-06-26

Family

ID=22564393

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431568T Expired - Fee Related DE69431568T2 (de) 1993-11-24 1994-11-22 Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen

Country Status (12)

Country Link
US (1) US5393772A (de)
EP (1) EP0741567B1 (de)
JP (1) JPH09505809A (de)
KR (1) KR100386229B1 (de)
CN (1) CN1102388C (de)
AT (1) ATE226072T1 (de)
AU (1) AU686706B2 (de)
CA (1) CA2176377A1 (de)
DE (1) DE69431568T2 (de)
ES (1) ES2185691T3 (de)
WO (1) WO1995014384A1 (de)
ZA (1) ZA949246B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US6075040A (en) 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
TR199900370T2 (xx) * 1996-08-23 1999-05-21 Boehringer Mannheim Pharma. Corp.-Smithkline Beecham Corp. Fas salg�lanmas�n� engelleme y�ntemi.
ATE215369T1 (de) 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
CZ123099A3 (cs) * 1996-10-09 1999-11-17 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corporation Limited Partnership No. 1 Farmaceutický prostředek pro inhibici stresem-aktivovaných protein kinas
AU765934B2 (en) * 1996-10-09 2003-10-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership No. 1 Method for inhibiting stress-activated protein kinases
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
DE19830472B4 (de) * 1998-07-08 2013-06-27 Robert Bosch Gmbh Externe Komponente für ein Mikroprozessorsystem und Betriebsverfahren
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
CA2424029C (en) * 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
JP2005507899A (ja) * 2001-09-28 2005-03-24 エフ．ホフマン−ラ　ロシュ　アーゲー カルベジロールの疑似多形形態
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1499310A4 (de) * 2002-04-30 2005-12-07 Sb Pharmco Inc Carvedilolmonocitrat-monohydrat
JP2005533823A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド リン酸カルベジロール塩および／またはその溶媒和物、対応する組成物、および／または治療方法
WO2004002472A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
EP1686986A4 (de) * 2003-11-25 2009-05-27 Sb Pharmco Inc Carvedilol-salze, entsprechende zusammensetzungen, verfahren zur abgabe und/oder behandlung
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
EP1686967A4 (de) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol-freie base, salze, wasserfreie formen oder solvate davon, entsprechende pharmazeutische zusammensetzungen, formulierungen mit kontrollierter freisetzung und behandlungs- oder abgabeverfahren
US10281374B2 (en) * 2015-11-04 2019-05-07 Diagnostic Biosystems Method of pretreatment of biological samples for an analyte-staining assay method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation

Also Published As

Publication number Publication date
KR100386229B1 (ko) 2003-08-21
EP0741567A4 (de) 1996-12-04
AU686706B2 (en) 1998-02-12
ES2185691T3 (es) 2003-05-01
EP0741567B1 (de) 2002-10-16
US5393772A (en) 1995-02-28
CA2176377A1 (en) 1995-06-01
JPH09505809A (ja) 1997-06-10
CN1102388C (zh) 2003-03-05
AU1186795A (en) 1995-06-13
WO1995014384A1 (en) 1995-06-01
ZA949246B (en) 1995-07-04
EP0741567A1 (de) 1996-11-13
CN1135161A (zh) 1996-11-06
ATE226072T1 (de) 2002-11-15
DE69431568D1 (de) 2002-11-21

Similar Documents

Publication Publication Date Title
DE69431568D1 (de) Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen
TW325458B (en) Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
NO943877D0 (no) Hemming av proliferasjon av glatte muskelceller og restenose
IL111258A0 (en) Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
DE69831937D1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
IL126339A0 (en) Taxol derivatives
DE69827777D1 (de) Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie
MY119150A (en) Azetidine derivatives, their preparation and medicaments containing them
CA2122360A1 (en) Quinazolinone Antianginal Agents
MY108885A (en) Heterocyclic-cyclic amine derivatives.
NO306063B1 (no) Kondenserte sykliske forbindelser og squalen syntetasehemmere
AU671933B2 (en) The administration of monoamine acridine in cholinergic neuronal deficit states
MX9707192A (es) Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas.
NO996578L (no) Urokinase-inhibitorer
BR0011865A (pt) derivados aromáticos e heterocìclicos de fitoteróis e/ou fitostanóis para uso no tratamento e prevenção de doença cardiovascular
DE69227088D1 (de) Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln
EP0572635A4 (de) Verbindungen met Guanidin Struktur und diese enthaltende pharmazeutische Zusammenstellungen.
TW223016B (de)
GB2311780B (en) Pharmaceutical Piperazine Compounds
DE69405760T2 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
NO994902L (no) Forebygging av brystkreft ved selektive östrogenreseptormodulatorer
ES2184885T3 (es) Derivados aza-antraciclinona.
NO952559L (no) N-acyl-pyrrolidiner og medikamenter for behandling eller prevensjon av cholecystokinin- og gastrin-relaterte mangler
AU6630796A (en) 1,9-diazabicyclo(4.3.0)nona-3,8-diene derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee